Gilbert Christopher R, Meggyesy Austin M, Bograd Adam J, Chiu Shih Ting, Wilshire Candice L, Gorden Jed A
Section of Interventional Pulmonology, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, SC.
The Center for Lung Research in Honor of Wayne Gittinger, Seattle, WA.
J Bronchology Interv Pulmonol. 2024 Jan 1;31(1):49-56. doi: 10.1097/LBR.0000000000000929.
Symptomatic pleural effusions and anticoagulant/antiplatelet medication use in postoperative cardiac surgery are common. Guidelines and recommendations are currently mixed regarding medication management related to invasive procedure performance. We aimed to describe the outcomes of postoperative cardiac surgery patients referred for outpatient, symptomatic pleural effusion management.
A retrospective study of post-cardiac surgery patients undergoing outpatient thoracentesis from 2016 to 2021 was performed. Demographics, operative details, pleural disease characteristics, outcomes, and complications were collected. Odds ratios with confidence intervals were estimated and adjusted by multivariate logistic regression to investigate the association with multiple thoracenteses.
A total of 110 patients underwent 332 thoracenteses. The median age was 68 years and most common operation was coronary artery bypass. Anticoagulation or antiplatelet use was identified in 97%. Thirteen complications were identified, with all major complications (n=3) related to bleeding. The amount of fluid present at the time of initial thoracentesis (>1500 milliliters) was associated with increased odds ratio of subsequent multiple thoracentesis (Unadjusted odds ratio, 6.75 (CI - 1.43 to 31.9). No other variables had a significant association with the need for multiple procedures.
Within a postoperative cardiac surgery population presenting with symptomatic pleural disease, we observed that thoracentesis performed on antiplatelet and/or anticoagulant medication is relatively safe. We also identified that many patients can be managed as outpatients and that most pleural effusions remain self-limited. The presence of larger amounts of pleural fluid at initial thoracentesis may be associated with increased odds for additional drainage.
术后心脏手术后出现症状性胸腔积液和抗凝/抗血小板药物的使用很常见。目前,关于与侵入性操作相关的药物管理,指南和建议存在差异。我们旨在描述接受门诊胸腔积液管理的心脏手术后患者的结局。
对 2016 年至 2021 年期间接受门诊胸腔穿刺术的心脏手术后患者进行回顾性研究。收集人口统计学、手术细节、胸腔疾病特征、结局和并发症。通过多元逻辑回归估计并调整比值比,以研究与多次胸腔穿刺相关的关联。
共有 110 例患者进行了 332 次胸腔穿刺术。中位年龄为 68 岁,最常见的手术是冠状动脉旁路移植术。97%的患者使用抗凝或抗血小板药物。共发现 13 种并发症,所有主要并发症(n=3)均与出血有关。初次胸腔穿刺时存在的液体量(>1500 毫升)与随后多次胸腔穿刺的几率增加相关(未调整比值比,6.75(CI-1.43 至 31.9)。没有其他变量与需要多次手术有显著关联。
在出现症状性胸腔疾病的术后心脏手术人群中,我们观察到在使用抗血小板和/或抗凝药物时进行胸腔穿刺术相对安全。我们还发现,许多患者可以作为门诊患者进行管理,并且大多数胸腔积液是自限性的。初次胸腔穿刺时存在更多量的胸腔积液可能与增加额外引流的几率相关。